Romosozumab: Bone-forming agent promising for osteoporosis patients

Romosozumab, A new bone-forming agent currently under study by Amgen Inc. and Belgium’s UCB, has shown promise in research into osteoporosis in postmenopausal women with low bone mineral density (BMD).